MPV, NLR, and platelet count: new hematologic markers in diagnosis of malignant ovarian tumor

Objective: Evaluation of mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR), and platelet count in the detection of malignant and benign ovarian tumors. Material and Methods: Sixty-six patients admitted to the present clinic over three years were included in the study. Patients diagnosed with ovarian cancer were grouped into the areas of epithelial and granulosa cell tumor diagnosis. The values were compared to patients with benign cystic structure. Patients’ preoperative hematologic parameters and their values four weeks postoperatively were analyzed. Statistical analyses were performed with SPSS software. Results: MPV, NLR, and platelet count were observed at a higher rate as statistically significant in patients diagnosed with malignant ovarian cancer, compared to those with benign adnexal mass. Conclusion: The hematological parameters such as MPV, NLR, and platelet count in the detection of malignant ovarian tumors have been evaluated as useful new markers.

Malignant; MPV; NLR; Ovarian tumors.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics”. CA Cancer J. Clin., 2013, 63, 11.

[2] Cannistra S.A.: “Cancer of the ovary”. N. Eng. J. Med., 2004, 351, 2519.

[3] De Angelis R., Sant M., Coleman M.P., Francisci S., Baili P., Pierannunzio D., et al.: “Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE−5 a population based study”. Lancet Oncol., 2014, 15, 23.

[4] Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C.: “Reactivity of a monoclonal antibody with human ovarian carcinoma”. J. Clin. Invest., 1981, 68, 1331.

[5] Chudecka-Głaz A.M.: “ROMA, an algorithm for ovarian cancer”. Clin. Chim. Acta, 2014, 440C, 143.

[6] Kim D.K., Oh S.Y., Kwon H.C., Lee S., Kwon K.A., Kim B.G.: “Clinical signifi cances of preoperative serum interleukin-6 and Creactive protein level inoperable gastric cancer”. BMC Cancer, 2009, 9, 155.

[7] Kemal Y., Demirag G., Ekiz K., Yucel I.: “Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer”. J. Obstet. Gynaecol., 2014, 34, 515.

[8] Falconer H., Yin L., Grönberg H., Altman D.: “Ovarian cancer risk after salpingectomy: a nationwide population-based study”. J. Natl. Cancer Inst., 2015, 107, pii: dju410.

[9] Fleming J.S., Beaugi C.R., Haviv I., Chenevix-Trench G., Tan O.L.: “Incessant ovulation, infl ammation and epithelial ovarian carcinogenesis: revisiting old hypotheses”. Mol. Cell. Endocrinol., 2006, 247, 4 .

[10] Riman T., Nilsson S., Persson I.R.: “Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies”. Acta Obstet. Gynecol. Scand., 2004, 883, 783.

[11] Mangalpally K.K., Siqueiros-Garcia A., Vaduganathan M., Dong J.F., Kleiman N.S., Guthikonda S.: “Platelet activation patterns in platelet size subpopulations: diff erential responses to aspirin in vitro”. J. Thromb. Thrombolysis, 2010, 30, 251.

[12] Kisucka J., Butterfield C.E., Duda D.G., Eichenberger S.C., Saff aripour S.,Ware J., et al.: “Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage”. Proc. Natl. Acad. Sci. U S A, 2006, 103, 855.

[13] Naina H.V., Harris S.: “Paraneoplastic thrombocytosis in ovarian cancer”. N. Engl. J. Med., 2012, 366, 1840.

[14] Tuszynski G.P., Nicosia R.F.: “The role of thrombospondin-1 in tumor progression and angiogenesis”. Bioessays, 1996, 18, 71.

[15] Chen Y.P., Chen C., Mai Z.Y., Gao J., Shen L.J., Zhao B.C., et al.: “Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients”. Oncol. Lett., 2015, 9, 1458.

[16] Qi Q., Geng Y., Sun M., Wang P., Chen Z.: “Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer”. Pancreatology, 2015, 15, 145.

[17] Ji W.H., Jiang Y.H., Ji Y.L., Li B., Mao W.M.: “Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy”. Dis. Esophagus, 2015, doi: 10.1111/dote.12322. [Epub ahead of print]

[18] Zhang W., Yu C., Huang B., Zhou F.L., Huang H.D., Li Q.: “Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients”. Oncol. Lett., 2015, 9, 762.

[19] Inagaki N., Kibata K., Tamaki T., Shimizu T., Nomura S.: “Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer”. Lung Cancer, 2014, 83, 97.

[20] Kokcu A., Kurtoglu E., Celik H., Tosun M., Malatyalıoglu E., Ozdemir A.Z.: “May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer?” Asian Pac. J. Cancer Prev., 2014, 15, 9781.

[21] Yildirim M.A., Seckin K.D., Togrul C., Baser E., Karsli M.F., Gungor T., Gulerman H.C.: “Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses”. Asian Pac. J. Cancer Prev., 2014, 15, 6881.

[22] Topcu H.O., Guzel A.I., Ozer I., Kokanali M.K., Gokturk U., Muftuoglu K.H., Doganay M.: “Comparison of neutrophil/lymphocyte and platelet/ lymphocyte ratios for predicting malignant potential of suspicious ovarian masses in gynecology practice”. Asian Pac. J. Cancer Prev., 2014, 15, 6239.

[23] Oge T., Yalcin O.T., Ozalp S.S., Isikci T.: “Platelet volume as a parameter for platelet activation in patients with endometrial cancer”. J. Obstet. Gynaecol., 2013, 33, 301